An overview of average market capitalization decline among European quoted biotech companies in the year beginning September 2001.
You may also be interested in...
The Neuer Markt's fall from grace is more than a reflection of the global market slump. Having soared faster and higher than most other markets, Germany's growth exchange is now suffering the worst. And its recovery is likely to take longer.
Using artificial intelligence and coronary computed tomography angiography Cleerly is trying to shift cardiology's focus from symptoms-based interventions to prevention and treatment of the underlying vascular disease.
Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.